Banque Cantonale Vaudoise Has $6.81 Million Stock Position in Amgen Inc. (NASDAQ:AMGN)

Banque Cantonale Vaudoise trimmed its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 35.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 21,142 shares of the medical research company's stock after selling 11,574 shares during the period. Banque Cantonale Vaudoise's holdings in Amgen were worth $6,812,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in AMGN. Hillsdale Investment Management Inc. increased its stake in shares of Amgen by 44.3% during the first quarter. Hillsdale Investment Management Inc. now owns 1,400 shares of the medical research company's stock worth $398,000 after purchasing an additional 430 shares during the period. Bessemer Group Inc. increased its position in Amgen by 29.3% during the first quarter. Bessemer Group Inc. now owns 37,202 shares of the medical research company's stock worth $10,578,000 after acquiring an additional 8,441 shares during the period. CANADA LIFE ASSURANCE Co raised its stake in Amgen by 2.7% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 49,931 shares of the medical research company's stock worth $14,241,000 after purchasing an additional 1,311 shares in the last quarter. InterOcean Capital Group LLC boosted its holdings in Amgen by 3.7% in the 1st quarter. InterOcean Capital Group LLC now owns 7,055 shares of the medical research company's stock valued at $2,006,000 after purchasing an additional 250 shares during the period. Finally, Ossiam grew its position in shares of Amgen by 154.2% during the 1st quarter. Ossiam now owns 49,414 shares of the medical research company's stock worth $14,049,000 after purchasing an additional 29,975 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

AMGN has been the subject of several recent research reports. Cantor Fitzgerald reiterated an "overweight" rating and issued a $405.00 price target on shares of Amgen in a research note on Tuesday, October 22nd. Truist Financial lowered Amgen from a "buy" rating to a "hold" rating and increased their target price for the stock from $320.00 to $333.00 in a report on Monday, October 14th. Sanford C. Bernstein started coverage on Amgen in a research note on Thursday, October 17th. They issued an "outperform" rating and a $380.00 price target for the company. Wells Fargo & Company downgraded shares of Amgen from an "overweight" rating to an "equal weight" rating and increased their price objective for the stock from $320.00 to $335.00 in a research note on Wednesday, August 7th. Finally, Deutsche Bank Aktiengesellschaft restated a "hold" rating and issued a $305.00 target price (down from $310.00) on shares of Amgen in a research report on Wednesday, August 7th. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $333.57.

Amgen Trading Up 0.4 %

Shares of NASDAQ:AMGN traded up $1.19 during mid-day trading on Tuesday, reaching $279.95. 3,210,343 shares of the company's stock were exchanged, compared to its average volume of 2,459,217. The business's fifty day moving average price is $319.90 and its 200-day moving average price is $318.65. Amgen Inc. has a twelve month low of $260.52 and a twelve month high of $346.85. The firm has a market capitalization of $150.48 billion, a price-to-earnings ratio of 35.69, a PEG ratio of 2.53 and a beta of 0.60. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.96 and a current ratio of 1.32.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, topping analysts' consensus estimates of $5.11 by $0.47. The company had revenue of $8.50 billion for the quarter, compared to analyst estimates of $8.50 billion. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The firm's quarterly revenue was up 23.2% on a year-over-year basis. During the same period in the previous year, the firm earned $4.96 earnings per share. On average, research analysts predict that Amgen Inc. will post 19.51 EPS for the current fiscal year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 9th. Shareholders of record on Monday, November 18th will be paid a $2.25 dividend. This represents a $9.00 annualized dividend and a yield of 3.21%. The ex-dividend date of this dividend is Monday, November 18th. Amgen's dividend payout ratio (DPR) is presently 115.24%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.